The new MACSQuant(TM) Analyzer combines cell enrichment and flow cytometry
16.01.2009, 09:00
Bergisch Gladbach (Germany) 16 January (PROTEXT/ots) - Miltenyi Biotec announces the worldwide release of the MACSQuant(TM) Analyzer, a novel and compact flow cytometer for multiparameter cell analysis. With this instrument launch Miltenyi Biotec broadens the product portfolio of the cell analysis business section and offers customers a milestone flow cytometer with novel features. "Whether working with one or 96 samples, the MACSQuant Analyzer can efficiently perform sample labeling and sensitive 7-color flow analysis in a fully automated fashion," states Product Manager Dr. Craig Fuller. "Rare cell populations can be reliably and reproducibly analyzed by enrichment of target cells using the integrated MACS(R) Cell Enrichment Unit and MACS(R) Technology," he continues. "With a wide range of reagents to choose from, the possibilities for the analysis of rare cells are extensive." The MACSQuant Analyzer boasts many additional features, such as absolute cell counting, remote instrument control, and automated instrument housekeeping procedures. All of this is touchscreen-operated using an intuitive, user-friendly program: the MACSQuantify(TM) Software. These outstanding features create an ideal instrument for core facilities, departmental collaborations, and individual laboratories. More details are provided at http://www.macsquant.com<\/A>.
Contact
Prof. Dr. Uwe Heinlein, Corporate Communications, Miltenyi Biotec GmbH
Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany
Phone: +49 2204 8306-6590
E-mail: uweh@miltenyibiotec.de<\/A>
Internet: http://www.miltenyibiotec.com<\/A>
About Miltenyi Biotec
The company is one of the largest and most successful biotechnology companies in Germany. More than 1,100 employees develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.